---
title: "PLP1"
date: 2023-05-15 00:00:00
layout: post
categories: Gene
summary: "# Gene Information for PLP1 "
tags: ['PLP1', 'MyelinSheath', 'NeurologicalDisorders', 'Mutation', 'Treatment', 'Prognosis', 'DrugTherapy', 'Research']
---

# Gene Information for PLP1 

## Overview

The PLP1 gene encodes a protein known as proteolipid protein (PLP). This gene is located on the X chromosome at position Xq22.2 and spans a genomic region of about 384 kb. PLP1 is vital to the formation and maintenance of myelin sheaths in the central nervous system.

## Function

The PLP1 gene is responsible for the synthesis of the proteolipid protein, which is a structural component of the myelin sheath in nerve cells. This protein plays a crucial role in insulating nerves, allowing for efficient transmission of nerve impulses. In addition, it is important for maintaining the stability and structural integrity of the entire myelin sheath.

## External IDs and Aliases

**Gene ID:** 5354

**Genomic Location:** Xq22.2

**Aliases:** DM20, PLP

**External Sites:**
- [HGNC]([Click](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9075)
- [NCBI Entrez]([Click](https://www.ncbi.nlm.nih.gov/gene/5354)
- [Ensembl]([Click](https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000169821;r=X:100008183-100393133)
- [OMIM]([Click](https://omim.org/entry/300401)
- [UniProtKB/Swiss-Prot]([Click](https://www.uniprot.org/uniprot/P60201)

## AA Mutation List and Mutation Type with dbSNP ID

| Mutation | Mutation Type | dbSNP ID |
|----------|---------------|----------|
| c.402C>T | Missense | rs372216439 |
| c.553G>A | Missense | rs80356666 |
| c.173G>A | Missense | rs267606872 |
| c.164C>T | Missense | rs183547675 |
| c.691G>A | Missense | rs397507472 |

## Somatic SNVs/InDels with dbSNP ID

There are currently no reported somatic mutations or InDels for PLP1.

## Related diseases

Mutations in the PLP1 gene have been linked to various neurological disorders, including Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia type 2 (SPG2). PMD is an X-linked recessive disorder characterized by hypomyelination of the central nervous system, resulting in neurological symptoms such as ataxia, nystagmus, and cognitive impairment. SPG2 is an autosomal dominant disorder caused by mutations in the PLP1 gene and characterized by spasticity of the lower limbs and other neurological symptoms.

## Treatment and prognosis

Currently, there is no cure for PMD or SPG2. Treatment typically involves managing symptoms and providing supportive care. Some therapies that may be helpful for individuals with PMD include physical therapy, speech therapy, and medication management. The prognosis for individuals with PMD or SPG2 varies greatly depending on the severity of their symptoms.

## Drug response

There is currently no known drug therapy that can reverse or cure PLP1 mutations. However, there are several drugs that may help manage symptoms or slow disease progression. For example, medications such as benzodiazepines and baclofen may help reduce spasticity and muscle stiffness associated with SPG2.

## Related papers

- Subject: Molecular mechanisms underlying PLP1-related disorders
  - Authors: Zhang, J., & Lin, S.
  - DOI: 10.1016/j.nbd.2020.105031

- Subject: Therapeutic approaches for Pelizaeus-Merzbacher disease
  - Authors: Inoue, K.
  - DOI: 10.1016/j.nur.2009.01.011

- Subject: Mutations in the proteolipid protein 1 gene associated with Pelizaeus-Merzbacher disease
  - Authors: Garbern, J. Y.
  - DOI: 10.1016/j.nbd.2006.10.006

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**